Singapore markets open in 4 hours 23 minutes

Petlife Pharmaceuticals, Inc. (PTLF)

OTC Markets EXMKT - OTC Markets EXMKT Delayed price. Currency in USD
Add to watchlist
0.0001+0.0001 (0.00%)
At close: 04:00PM EDT

Petlife Pharmaceuticals, Inc.

8033 Sunset Boulevard
Suite 867
Los Angeles, CA 90046
United States

IndustryDrug Manufacturers - Specialty & Generic
Full-time employees1

Key executives

NameTitlePayExercisedYear born
Mr. Sebastian Serrell-WattsChairman, CEO, President, CFO, Secretary & TreasurerN/AN/A1965
Dr. Arthur Grant Mikaelian Ph.D.Founder and Chief Scientific Officer110.4kN/A1962
Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.

Corporate governance

Petlife Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.